The elucidation of the incretin-insulin pathway prompted the development of DPP-4 inhibitors to prolong the circulating half-life of endogenous incretins to achieve glycemic control in diabetes patients, with a focus on drugs that can be taken orally. The gene discussed is GCG; the disease is diabetes mellitus.